Taglich Brothers Initiates Coverage of Cosmos Health Inc.
CHICAGO, IL / ACCESSWIRE / February 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
COVID-19
Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study
Innovative approaches in MRI technology demonstrate the potential of portable ultra-low-field MR brain imaging to aid physicians in the diagnosis...
Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study
Innovative approaches in MRI technology demonstrate the potential of portable ultra-low-field MR brain imaging to aid physicians in the diagnosis...
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira’s Products
Correction: Extended clarification.HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide...
Corporate Update on Clinical Evaluation of MedMira’s Products
HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update...
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live...
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides – NV-387 Could be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Panbela Announces Closing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of...
Legacy Novozymes delivers solid last full-year results
Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales...
Moderna Named to Fortune’s List of World’s Most Admired Companies
CAMBRIDGE, MA / ACCESSWIRE / January 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been recognized on Fortune's...
Open Letter to Zomedica Shareholders from your Chief Executive Officer
ANN ARBOR, MI / ACCESSWIRE / January 31, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
HCA Healthcare Reports Fourth Quarter 2023 Results and Provides 2024 Guidance
Bill Rutherford to Retire and Mike Marks to Become CFONASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and...
CorVel Announces Revenues and Earnings
FORT WORTH, Texas, Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended...
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong...
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
Science 37 stockholders to receive $5.75 per share in cashRESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science...
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared...
Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote “FOR” Proposed Reverse Stock Split
ANN ARBOR, MI / ACCESSWIRE / January 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...